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ABSTRACT
Purpose: The aim of this study was to study temporal changes in metabolite profiles in patients with
post-acute coronary syndrome (ACS), in particular prior to the development of recurrent ACS (reACS).
Methods: BIOMArCS (BIOMarker study to identify the Acute risk of a Coronary Syndrome) is a pro-
spective study including patients admitted for ACS, who underwent high-frequency blood sampling
during 1-year follow-up. Within BIOMArCS, we performed a nested case-cohort analysis of 158 patients
(28 cases of reACS). We determined 151 metabolites by nuclear magnetic resonance in seven (median)
blood samples per patient. Temporal evolution of the metabolites and their relation with reACS was
assessed by joint modelling. Results are reported as adjusted (for clinical factors) hazard ratios (aHRs).
Results: Median age was 64 (25th–75th percentiles; 56–72) years and 78% were men. After multiple test-
ing correction (p< 0.001), high concentrations of extremely large very low density lipoprotein (VLDL) par-
ticles (aHR 1.60/SD increase; 95%CI 1.25–2.08), very large VLDL particles (aHR 1.60/SD increase; 95%CI
1.25–2.08) and large VLDL particles (aHR 1.56/SD increase; 95%CI 1.22–2.05) were significantly associated
with reACS. Moreover, these longitudinal particle concentrations showed a steady increase over time prior
to reACS. Among the other metabolites, no significant associations were observed.
Conclusion: Post-ACS patients with persistent high concentrations of extremely large, very large and
large VLDL particles have increased risk of reACS within 1 year.
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Introduction
In recent years, the rise of genomics has helped to unravel
the human genome and to identify genes that are involved
with the development of cardiovascular disease (CVD)
(O’Donnell and Nabel 2011). However, CVD is a polygenic and
multifactorial disease, which is both influenced by a patient’s
genetic predisposition and affected by biological and chemical
variation downstream of the genetic code. Although genomic
research concentrates on the ‘static’ genotype of a patient,
metabolomic research focuses on metabolites, which are the
substrates or end-products of all enzymatic processes (Shah
and Newgard 2015). Metabolomic research creates a blueprint
of a patient’s metabolism at a specific time point and, accord-
ingly, captures both the upstream influence of a patient’s
genotype and downstream variation influencing the metabol-
ism (Shah and Newgard 2015). Eventually, combining know-
ledge gained through metabolomic research with knowledge
on genetics and clinical risk factors may give rise to novel
insights on the pathophysiology of CVD.
Clinical significance
 Repeatedly measured metabolites carry incremental
prognostic information in patients with post-ACS
prior to a recurrent ACS event over a single baseline
measurement.
 Extremely large VLDL, very large VLDL and large VLDL
particle concentrations steadily increase prior to a recur-
rent ACS in patients with post-ACS.
 Higher extremely large VLDL, very large VLDL and large
VLDL particle concentrations in patients with post-ACS
are associated with a higher risk of developing reACS
within 1 year after initial ACS admission.
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The number of longitudinal studies that have assessed the
association between a patient’s metabolite profile and devel-
opment of CVD is increasing (Ruiz-Canela et al. 2017).
However, these studies relate single baseline measurements
to the incidence of CVD events during long-term follow-up
(Ruiz-Canela et al. 2017). Since the metabolite profile of
patients with CVD is not a static given, but will likely be
influenced by changes in disease severity over time, repeated
metabolite profile measurements might carry incremental
prognostic information over a single measurement.
We designed the ‘BIOMarker study to identify the Acute
risk of a Coronary Syndrome’ (BIOMArCS) to study temporal
biomarker changes in patients with post-acute coronary syn-
drome (ACS). This report describes an analysis of the temporal
patterns of 151 metabolites in these patients and the associ-
ation of the repeatedly measured metabolites with reACS.
Methods
Study population
BIOMArCS is a multicentre observational study, conducted
during 2008–2015 in the Netherlands. Details concerning the
study design have been described elsewhere (Oemrawsingh
et al. 2016). In brief, BIOMArCS enrolled patients who were
admitted for ACS, either with or without ST elevation, and
who had at least one additional CVD risk factor. After inclu-
sion, venipuncture was performed at admission, discharge,
and subsequently every 2 weeks during the first half-year
and every 4 weeks during the second half-year. If logistic cir-
cumstances hindered inclusion during hospitalization,
patients could be included on the first outpatient visit within
6weeks after discharge – the absence of early samples was
then accepted. Samples were collected non-fasting.
BIOMArCS was approved by the Institutional Review
Boards of all enrolling hospitals, and all participating patients
provided written informed consent. BIOMArCS is registered
in the Netherlands Trial Register as NTR1698 and NTR1106.
Study design
BIOMArCS enrolled 844 patients, and 45 reached the study
endpoint of reACS, defined as a cardiac death, non-fatal
myocardial infarction (MI) or unstable angina (UA) requiring
urgent coronary revascularization (endpoint cases). For rea-
sons of cost-efficiency, we applied a case-cohort design with
respect to the present metabolite analysis (patient selection
is shown in Figure 1). A case-cohort design is a pragmatic
way to simulate the results, which could have been found in
a full cohort (Boersma et al. 2019). A random sample of 150
patients was selected from the full cohort (which rendered
eight endpoint cases), and was complemented with the
remaining 37 endpoint cases outside this random sample.
Consequently, the case-cohort sample included all 45 study
endpoint cases and 142 endpoint-free patients.
We realized that the metabolites could have been influ-
enced by the index ACS event. We were mainly interested in
metabolite patterns after clinical stabilization. Therefore, we
restricted our analyses to the 28 study endpoint cases and
130 event-free patients with available blood samples after
30 days following the index event.
Metabolite analysis
Serum samples were collected and preserved on-site at
80 C. Subsequently, samples were transported to the
Erasmus MC for long-term storage under the same condi-
tions. For the current analysis, serum samples were analysed
applying high-throughput automated proton nuclear mag-
netic resonance (NMR) spectroscopy by Nightingale Health
(Soininen et al. 2015). In each blood sample, all metabolites
were quantified simultaneously, and, subsequently, expressed
in absolute concentrations using Nightingale Health’s propri-
etary software (Soininen et al. 2015). Details on the applied
NMR method are described in the Supplementary Material.
The NMR method provided the molar concentrations of 151
metabolites, including 14 lipoprotein subclasses and their
particle concentrations and lipids compositions, 9 cholesterol
metabolites, 2 apolipoproteins, 8 glycerides and phospholi-
pids, 9 fatty acids, 4 glycolysis related metabolites and 9
amino acids.
Statistical data analysis
Continuous variables are presented as median (25th–75th
percentiles). Categorical variables are presented as number
(percentage). Differences in continuous data between study
endpoint cases and event-free patients were evaluated by
Mann–Whitney U-tests, whereas categorical variables were
evaluated by Pearson Chi-square tests.
The linear mixed effects (LME) model was used to
describe the evolution of metabolites over time, with adjust-
ment for age, gender, GRACE risk score, diabetes mellitus,
history of peripheral arterial disease, statin use and vitamin K
antagonist use. Cox proportional hazard regression was used
to relate serially measured metabolite level, based on the
Figure 1. Patient flow chart. First, a random sample of 150 patients of our full
cohort (844) was selected which rendered eight endpoint cases, which was
then complemented with all endpoint cases outside the random sample.
Consequently, the case-cohort sample included all 45 study endpoint cases and
142 endpoint-free patients. Blood samples were available of 158 patients 30
days post the index event.
2 M. M. VROEGINDEWEY ET AL.
LME model, with the incidence of the study endpoint, while
adjusting for GRACE risk. The parameters of the LME and Cox
models were estimated in a joint model to avoid bias
(Rizopoulos 2016). To enable a direct comparison of the rela-
tion between different metabolites and the study endpoint,
we present adjusted hazard ratios (aHRs) as per one standard
deviation (SD) difference.
R statistical software (version 3.4.3) was used for the stat-
istical analyses, in particular the package JMbayes
(Rizopoulos 2016). All statistical tests were two-tailed, and p-
values <0.001 were considered statistically significant, to cor-
rect for multiple testing. This significance level was deter-
mined by matrix spectral decomposition (Li and Ji 2005).
Results
Median (25th–75th percentiles) age was 63.8 (56.1–71.6)
years and 77.8% were men. Study endpoint cases were older
than event-free patients, had a higher prevalence of dia-
betes, history of peripheral arterial disease and vitamin K
antagonist usage (Table 1), and had similar characteristics
otherwise. For the current analysis, a median (25th–75th per-
centiles) of 7 (3–10) and 8 (5–9) repeated measurements
were available in study endpoint cases and event-free
patients, respectively.
In addition, 95% of the 1101 samples were collected in
patients on statins. Clinical characteristics did not signifi-
cantly differ between statin-treated and statin-untreated
patients (data not shown). Low-density lipoprotein (LDL)
cholesterol was 0.46 (95%CI: 0.061–0.85) mmol/l per SD
increase higher in the 55 samples collected in statin-
untreated patients (p¼ 0.024).
Metabolites
Higher concentrations of extremely large VLDL particles
(XXL-VLDL-P), very large VLDL-P (XL-VLDL-P) and large VLDL-
P (L-VLDL-P) were significantly associated with reACS (aHR
1.60/SD, 95% CI 1.25–2.08; aHR 1.60/SD, 95% CI 1.25–2.08;
aHR 1.56/SD, 95% CI 1.22–2.05, respectively) during 1-year
follow-up (Figure 2 and Supplemental Table S1). Moreover,
the concentrations of these particles steadily increased prior
to the reACS (Figure 3).
In addition to the lipoprotein subclass particle concentra-
tions, the lipid composition of each lipoprotein subclass was
quantified with NMR (Supplemental Table S2). A lipoprotein
particle is composed of phospholipids, cholesterol, choles-
terol esters, free cholesterol and triglycerides. Figure 4 shows
the aHR’s of the lipid components of XXL-VLDL-P, XL-VLDL-P
and L-VLDL-P. Overall, the individual lipid components of
Table 1. Baseline clinical characteristics.
Overall Event-free patients Cases p Value
No. of patients 158 130 28
Presentation and initial treatment
Men 123 (77.8) 102 (78.5) 21 (75.0) 0.88
Age – yr 63.8 (56.1–71.6) 62.3 (55.1–71.0) 68.0 (59.0–76.3) 0.030
Admission diagnosis 0.59
STEMI 69 (43.7) 59 (45.4) 10 (35.7)
NSTEMI 66 (41.8) 52 (40.0) 14 (50.0)
UAP 23 (14.6) 19 (14.6) 4 (14.3)
CAG performed 149 (94.3) 121 (93.1) 28 100.0) 0.33
PCI performed 124 (84.4) 100 (83.3) 24 (88.9) 0.67
CKMax – U/L 425.0 (179.0–1197.0) 452.5 (196.8–1200.8) 312.0 (135.0–750.5) 0.24
Cardiovascular risk factors
Smoking 0.89
Current 65 (41.1) 54 (41.5) 11 (39.3)
Former 48 (30.4) 40 (30.8) 8 (28.6)
Never 45 (28.5) 36 (27.7) 9 (32.1)
Diabetes mellitus 32 (20.3) 22 (16.9) 10 (35.7) 0.047
Hypertension 84 (53.2) 70 (53.8) 14 (50.0) 0.87
Hypercholesterolaemia 76 (48.1) 66 (50.8) 10 (35.7) 0.22
Creatinine – mmol/L 82.5 (72.3–93.8) 82.0 (73.0–91.8) 86.5 (71.3–95.0) 0.46
Cardiovascular history
Peripheral arterial disease 15 (9.5) 9 (6.9) 6 (21.4) 0.043
Myocardial infarction 51 (32.3) 42 (32.3) 9 (32.1) 1.00
PCI 47 (29.9) 37 (28.7) 10 (35.7) 0.61
CABG 16 (10.1) 11 ( 8.5) 5 (17.9) 0.25
Stroke 20 (12.7) 14 (10.8) 6 (21.4) 0.22
Valvular heart disease 5 (3.2) 2 (1.5) 3 (10.7) 0.055
Heart failure 7 (4.4) 4 (3.1) 3 (10.7) 0.20
Medication at first blood sample moment >7 days after the index ACS
Aspirin 150 (95.5) 122 (94.6) 28 (100.0) 0.45
P2Y12 inhibitor 145 (92.4) 118 (91.5) 27 (96.4) 0.62
Vitamin K antagonist 14 (8.9) 8 (6.2) 6 (21.4) 0.028
Statin 151 (96.2) 125 (96.9) 26 (92.9) 0.64
Beta-blocker 135 (86.0) 108 (83.7) 27 (96.4) 0.15
ACE inhibitor or ARB 131 (83.4) 105 (81.4) 26 (92.9) 0.23
The first blood sample >7 days was taken at a median (25th–75th percentiles) of 24 (16–34) days after the index ACS.
Continuous variables are presented as median (25th–75th percentiles). Categorical variables are presented as number (percentage).
ACE: angiotensin converting enzyme, ARB: angiotensin II receptor blocker, CABG: coronary artery bypass grafting, CKmax: maximum creatinine kin-
ase during the index admission, No: Numero, NSTEMI: non-ST-elevation myocardial infarction, PCI: percutaneous coronary intervention, STEMI: ST-
elevation myocardial infarction, Troponinmax: maximum troponin value during the index admission, UAP: unstable angina pectoris, yr: years.
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XXL-VLDL-P, XL-VLDL-P and L-VLDL-P were also associated
with reACS. However, per lipid component we observed
intra-variability (within the particle) and, more importantly,
inter-variability (between the particles) in the degree of asso-
ciation with reACS. For instance, in XXL-VLDL the concentra-
tion of total cholesterol was associated with reACS with an
aHR of 1.58/SD increase (95% CI: 1.18–1.94, p< 0.001). In XL-
VLDL, the concentration of total cholesterol had an aHR of
1.53/SD increase (95% CI: 1.19–1.97, p¼ 0.006). In L-VLDL, the
concentration of total cholesterol had an aHR of 1.34/SD
increase (95% CI: 0.89–1.98, p¼ 0.17).
Among the other assessed metabolite groups, no signifi-
cant associations were observed between metabolite concen-
tration and reACS.
Discussion
This study assessed the association between repeatedly meas-
ured metabolite profiles and the incidence of reACS during one
year follow-up in patients with post-ACS. Patients who experi-
enced reACS had steadily increasing concentrations of XXL-
VLDL-P, XL-VLDL-P and L-VLDL-P during 1-year of follow-up
until the moment of the endpoint event. No significant associa-
tions were observed between longitudinal serum concentra-
tions of cholesterol metabolites, apolipoproteins, glycerides and
phospholipids, fatty acids, glycolysis related metabolites or
amino acids and reACS. Hence, serial blood sampling may
benefit the prognostic accuracy of lipoprotein particle concen-
trations over a single baseline measurement. In a larger study
cohort with more patients developing cardiac outcome, one
should assess the frequency of sampling needed for accurate
prognostication using lipoprotein particle concentrations.
Our study predominantly consisted of statin-treated
patients. Previously, Wurtz et al. (2016) showed in a combined
analysis of population-based cohorts, that statin-use lowered
most of their NMR-quantified metabolite concentrations. In
particular, statins effectively lowered multiple lipoprotein con-
centrations in addition to LDL cholesterol. In our study, des-
pite statin use, XXL-VLDL-P, XL-VLDL-P and L-VLDL-P
concentrations were significantly higher in patients who expe-
rienced a reACS, whereas total VLDL cholesterol was not.
Since recent years, studies are advocating the added value of
lipoprotein particle concentrations to lipoprotein cholesterol
concentrations for clinical prognosis in patients with CVD
(Rosenson and Underberg 2013). Moreover, in 2011, the
American National Lipid Association Expert panel has advised
to study the use of lipoprotein particle concentrations to
enhance treatment management, to address the residual risk
of statin-treated patients with CVD for adverse outcome
(Davidson et al. 2011). Subsequently, several studies have
found that LDL particle concentration is a better predictor of
adverse outcome than LDL cholesterol in patients with CVD
on lipid-lowering treatment (Rosenson and Underberg 2013).
One can argue that the latter finding might also be true for
VLDL. It has been previously described that elevated VLDL
cholesterol levels are an independent predictor of adverse
outcome in the general population and in patients with CVD,
and it has been suggested that VLDL cholesterol in combin-
ation with LDL cholesterol may be a better determinant of
adverse outcome than LDL cholesterol alone (Sacks et al.
2000, Liu et al. 2006, Ren et al. 2010). In our study, we found
that the larger VLDL particle concentrations were associated
with reACS, whereas total VLDL cholesterol was not. Hence,
further research should establish if VLDL particle
Figure 2. Associations of NMR-quantified metabolite profile and reACS. aHR’s with 95%CI are presented on an SD scale adjusted for age, gender, GRACE risk score,
diabetes mellitus, history of peripheral arterial disease, statin use and vitamin K antagonist use. Black rounds are statistically significant with p< 0.001; grey trian-
gles are not. C: cholesterol; DHA: docosahexaenoic acid; HDL: high-density lipoprotein; IDL: intermediate-density lipoprotein; LDL: low-density lipoprotein; MUFA:
monounsaturated fatty acids; PUFA: polyunsaturated fatty; TG: triglycerides; VLDL: very low density lipoprotein.
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concentrations provide incremental prognostic information to
LDL particle concentrations in statin-treated patients with
CVD to address their risk of developing adverse outcome.
Although not significant, plasma glucose appeared to cor-
relate with reACS in our study. Previously, it has been dem-
onstrated that hyperglycaemia induces overproduction of
larger VLDL particles (Adiels et al. 2005). Thus, potentially,
the patients with post-ACS who experienced reACS had a
certain grade of hyperglycaemia which may have induced
the overproduction of larger VLDL particles and subsequent
pathological atherogenesis.
Currently, results obtained by metabolite profiling are dif-
ficult to compare across various study populations, due to
lack of a uniform way to quantify metabolites and otherwise
heterogeneous study methods (Ruiz-Canela et al. 2017).
Although NMR is a cost-effective tool to obtain detailed
knowledge on metabolites (Rankin et al. 2014), the sensitivity
of this technique is limited compared with other metabolite
profiling techniques such as mass spectrometry. Still, also
mass spectrometry has downsides, including automation of
the technique and the fact that it cannot detect lipoproteins
(Rankin et al. 2014). Therefore, in our view, NMR suits pur-
poses of epidemiological studies including ours, whereas
mass spectroscopy is more suited for detailed metabolite dis-
covery. Eventually, the field of CVD metabolite research
should focus on developing uniform study methods, as well
as profiling techniques to obtain more reliable and
Figure 3. Longitudinal trajectory of XXL-VLDL-P, XL-VLDL-P and L-VLDL-P prior
to reACS. nmol: nanomol; l: litre; L-VLDL-P: large VLDL particles; reACS: repeated
acute coronary syndrome; XXL-VLDL-P: extremely large VLDL particles; XL-VLDL-
P: very large VLDL particles.
Figure 4. Associations of NMR-quantified components of extremely large, very
large and large VLDL particles and reACS. aHR’s with 95%CI are presented on
an SD scale adjusted for age, gender, GRACE risk score, diabetes mellitus, his-
tory of peripheral arterial disease, statin use and vitamin K antagonist use.
Black rounds are statistically significant with p< 0.001; grey triangles are not.
VLDL: very low density lipoprotein.
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comparable results. Under such conditions, the knowledge
that will be gained through metabolite profiling might
enable a precision-medicine approach to CVD treatment.
Limitations
This study used 1101 serial blood samples to assess the time
course of NMR-quantified metabolites and their longitudinal
association with incident ACS. Nonetheless, as only 28 study
endpoint cases were available, we cannot exclude the possi-
bility that our study was underpowered. In addition, freezing
and thawing of serum samples could have influenced the
metabolite measurements. However, our samples were kept
frozen at 80 C throughout complete storage and transpor-
tation of the samples up until quantification. Lastly, because
of the exploratory character of our study, we could not pro-
vide a mechanical interpretation of our findings.
Conclusion
Post-ACS patients with persistent high concentrations of
extremely large, very large and large VLDL particles have
increased risk of reACS within 1 year.
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